Evaluation of the AccuPower® RV1 Real-Time RT-PCR Kit and the AccuPower® RV1 Multiplex Kit for SARS-CoV-2 and Influenza Virus Detection
김만진, 박현웅, 전유라, 신호섭, 조성임, 김보람, 이지수, 박성섭, 성문우,
소속 상세정보
김만진 ( Kim Man-Jin )
Seoul National University Hospital Department of Laboratory Medicine
박현웅 ( Park Hyun-Woong )
Seoul Metropolitan Government-Seoul National University Boramae Medical Center Department of Laboratory Medicine
전유라 ( Jeon You-La )
Green Cross Laboratories Department of Laboratory Medicine
신호섭 ( Shin Ho-Seob )
Seoul National University Hospital Department of Laboratory Medicine
조성임 ( Cho Sung-Im )
Seoul National University Hospital Department of Laboratory Medicine
김보람 ( Kim Bo-Ram )
Seoul National University Hospital Department of Laboratory Medicine
이지수 ( Lee Jee-Soo )
Seoul National University Hospital Department of Laboratory Medicine
박성섭 ( Park Sung-Sup )
Seoul National University Hospital Department of Laboratory Medicine
성문우 ( Seong Moon-Woo )
Seoul National University Hospital Department of Laboratory Medicine
Abstract
Background: The AccuPower® RV1 Real-Time RT-PCR Kit (Bioneer, Korea) and AccuPower® RV1 Multiplex Kit (Bioneer) are one-step real-time reverse transcription PCR assays for detecting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and influenza A and B.
Methods: We clinically evaluated the AccuPower® RV1 Real-Time RT-PCR Kit and AccuPower® RV1 Multiplex Kit by comparing their results for 1,098 clinical samples. The presence of SARS-CoV-2 was confirmed using the Allplex™ 2019-nCoV Assay (Seegene, Korea) and Standard M nCoV Real-Time Detection Kit (SD Biosensor, Korea). Influenza viruses were detected using the Allplex™ Respiratory Panel 1 (Seegene).
Results: The comparative positive and negative agreement values of the AccuPower® RV1 Real-Time RT-PCR Kit for SARS-CoV-2 and influenza A and B were 100%. The positive agreement of the AccuPower® RV1 Multiplex Kit was 100% for SARS-CoV-2 and 98.77% for influenza A and B. The kappa values for SARS-CoV-2 and influenza A and B were >0.99. SARS-CoV-2 was evaluated using both sputum and nasopharyngeal or oropharyngeal swabs. There was no difference in the detection rates for each type.
Conclusions: The findings confirm the clinically comparable performances of the AccuPower® RV1 Real-Time RT-PCR Kit and the AccuPower® RV1 Multiplex Kit.
키워드
SARS-CoV-2; Influenza virus; Multiplex real-time PCR; Clinical evaluation
원문 및 링크아웃 정보
등재저널 정보